Trials / Completed
CompletedNCT00041795
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- NeoTherapeutics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | leteprinim potassium (Neotrofin) |
Timeline
- Start date
- 2002-01-01
- First posted
- 2002-07-19
- Last updated
- 2005-06-24
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00041795. Inclusion in this directory is not an endorsement.